August 07, 2020
A customer report of a 20-mg tablet in a bottle labelled for 10-mg tablets has prompted Lupin Pharmaceuticals Inc. to voluntarily recall a single lot of 10-mg lisinopril tablets, according to the August 5, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects lisinopril tablets, 10 mg, 1000-count bottles (NDC 68001-334-08) from lot Q000232 (Exp. 1/22). The product, manufactured by Lupin Limited for BluePoint Laboratories, was distributed in Ohio but may have been further distributed throughout the United States.
Lupin Pharmaceuticals initiated the recall July 17, 2020. The FDA designated the recall Class II on July 28, 2020. Under Class II recalls, use of the product could cause temporary or medically reversible adverse health consequences, or a remote possibility of serious harm.
Lisinopril is a prescription angiotensin converting enzyme (ACE) inhibitor used to treat high blood pressure and heart failure, and to reduce the risk of death after heart attack.